EE284 Cost-Effectiveness of Pembrolizumab in Combination With Chemotherapy As First-Line Treatment of Advanced or Metastatic Esophageal Cancer or HER2-Negative Gastroesophageal Junction Adenocarcinoma in France
Dec 1, 2022, 00:00
10.1016/j.jval.2022.09.531
https://www.valueinhealthjournal.com/article/S1098-3015(22)02735-8/fulltext
Title :
EE284 Cost-Effectiveness of Pembrolizumab in Combination With Chemotherapy As First-Line Treatment of Advanced or Metastatic Esophageal Cancer or HER2-Negative Gastroesophageal Junction Adenocarcinoma in France
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(22)02735-8&doi=10.1016/j.jval.2022.09.531
First page :
Section Title :
Open access? :
No
Section Order :
10060